Russia claims 91.4% efficiency in new vaccine data Covid-19

From: Reuters | Moscow |

Updated: December 14, 2020 7:52:38 PM





A vaccine against Sputnik V was developed by the National Center of Epidemiology and Microbiology Gamaleya and Russian Direct Investment Fund (RDIF). (File)

Russia developers of coronavirus vaccine published recent results of their test on the Sputnik V vaccine on Monday based on new data, and said the shot was again 91.4% effective in protecting against Covid-19. The results are crucial for India, where the vaccine is being tested about people in middle to late stages of Drs Reddy-based Laboratories in Hyderabad.

More than 100,000 people have already been vaccinated against the disease as part of Russia’s mass inoculation program, which began in September along with a human trial of the shooting in Moscow. The new results are based on data from 22,714 participants in the trial, and were released after 78 confirmed coronavirus cases were reported among the group, researchers from the Gamaleya Institute said in a statement made Monday with the Russian Direct Investment Fund (RDIF), which markets the shot overseas.

Of the 78 cases, 62 occurred among participants who received a placebo, the researchers said, adding that in the trial overall the ratio of those who received the placebo to those who were vaccinated was 1 to 3. Twenty of those infected participants who received placebo suffered severe symptoms of Covid-19, the statement said.

Explained: Where are we in the Covid-19 vaccine race?

There were no severe cases of the disease among the 16 vaccinated participants, the statement said. “Analysis of the new data found that Sputnik V, named after the Soviet-era satellite that launched the space race, had an efficiency of 91.4%,” the statement said. The results, described as a “final checkpoint” in the test, were identical to provisional results published on 24 November, based on 39 cases of coronavirus among test participants, which also found the shot to be 91.4% effective.

“I believe we will be able to vaccinate most of the population in Russia in 2021,” director of the Gamaleya Institute
Alexander Gintsburg was quoted in the statement as saying. The data will be published by the Gamaleya Institute in an international medical journal by colleagues, according to the statement.

“We will certainly share the results achieved with the scientific community and will be happy to discuss them with all interested colleagues,” said Denis Logunov of Gamaleya Institute.

The results will also be used to send the shot for emergency use authorization in other countries. Tests of
Sputnik V continues in Belarus, the United Arab Emirates and Venezuela.

📣 The Indian Express is now at Telegram. Click here to join our channel (@indianexpress) and stay up to date with the latest headlines

For all the latest World News, download Indian Express Program.

Source